Aspect Partners
LEGN icon

Aspect Partners’s Legend Biotech LEGN Stock Holding History

Aspect Partners’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.36K Buy
169
+9
+6% +$192 ﹤0.01% 464
2026
Q2 		$4.62K Buy
160
+9
+6% +$243 ﹤0.01% 431
2026
Q1 		$2.73K Buy
151
+15
+11% +$286 ﹤0.01% 441
2025
Q4 		$2.96K Buy
+136
New +$3.9K ﹤0.01% 459

Other funds holding LEGN

Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
NLB Skladi upravljanje premozenja
NLB Skladi upravljanje premozenja Ljubljana $2.71B AUM 53.8% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
PensionDanmark
PensionDanmark Copenhagen O, Denmark $12.3B AUM 33.99% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return
Toth Financial Advisory
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Aspect Partners's LEGN Position: Q3 2026 in Review

Aspect Partners increased its Legend Biotech (LEGN) stake by 5.6% in Q3 2026, buying an estimated $192 and bringing the position to 169 shares worth $3.36K. The position accounts for ﹤0.01% of the portfolio, ranked #464.

Aspect Partners first reported a position in LEGN in Q4 2025 and has held it in 4 quarters since. The position peaked at $4.62K in Q2 2026. 19 funds tracked by Wall St. Rank hold LEGN as of Q3 2026.

  • Aspect Partners held 169 shares of Legend Biotech worth $3.36K as of Q3 2026.
  • Aspect Partners bought 9 Legend Biotech shares in Q3 2026, an estimated $192.
  • Legend Biotech made up ﹤0.01% of Aspect Partners's portfolio in Q3 2026, its #464 holding.
  • Aspect Partners first reported a position in Legend Biotech in Q4 2025 and has held it in 4 quarters since.
  • Aspect Partners's Legend Biotech position peaked at $4.62K in Q2 2026.
  • 19 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2026.

Based on Aspect Partners's 13F filing for Q3 2026, filed 20 Oct 2026.